INFU — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-04

• Net revenues for the quarter ended June 30, 2026 (“second quarter of 2026”) were $36.9 million, an increase of $0.9 million, or 2.6%, compared to $36.0 million for the quarter ended June 30, 2025 (“second quarter of 2025”). The increase included higher net revenues for the Patient Services segment p…

• Patient Services net revenue of $24.8 million increased $3.3 million, or 15.2%, during the second quarter of 2026 compared to the prior year period. This increase was primarily attributable to additional treatment volume and increased third-party payer collections in Oncology and Wound Care. The imp…

• Compression Devices (PCDs) and Adjustable Compression Wraps (ACW’s) stemming from two new supplier relationships. There was no PCD or ACW revenue in the second quarter of 2025 because the new products launched during the third quarter of 2025, with the first manufacturer, and during the first quarte…

• Gross profit for the second quarter of 2026 of $21.4 million increased by $1.5 million, or 7.7%, compared to the second quarter of 2025. This increase was due to the increase in net revenues and by a higher gross profit percentage of net revenue (“gross margin”). Gross margin was 58.0% during the se…

• Patient Services gross profit was $15.3 million during the second quarter of 2026, representing an increase of $1.5 million, or 10.9%, compared to the prior year period. The increase reflected the higher net revenue offset partially by lower gross margin, which decreased from the prior year by 2.4% …

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• Net revenues for the three-month period ended March 31, 2026 (“three-month period of 2026”) were $33.7 million, a decrease of $1.0 million, or 3.0%, compared to $34.7 million for the three-month period ended March 31, 2025 (“three-month period of 2025”). The decrease included lower net revenues for …

• Patient Services net revenue of $22.1 million increased $1.3 million, or 6.4%, during the three-month period of 2026 compared to the same prior year period. This increase was primarily attributable to additional treatment volume in Oncology

• and Wound Care which were partially offset by a lower amount in Pain Management. The improved volume and collections benefited Oncology revenue by $0.4 million or 2.4%, and Wound Care treatment revenue by $1.1 million, or 116.0%. Pain Management revenue decreased by $0.2 million, or 15.1%. The Wound…

• Gross profit of $19.7 million for the three-month period of 2026 increased $0.5 million, or 2.7%, from $19.2 million for the three-month period of 2025. This increase was due to the increase in gross margin partially offset by the lower net revenues. Gross margin increased to 58.4% during the three-…

• Patient Services gross profit was $14.3 million during the three-month period of 2026, representing an increase of $1.1 million, or 8.6%, compared to the same prior year period. The improvement reflected increased net revenue and a higher gross margin, which increased from the prior year by 1.3% to …

Text added vs the prior filing · source: 10-Q · 2026-08-04

• We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material informa…

• including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10…

• During the six-month period ended June 30, 2026, the Company migrated certain of our business applications and financial processing systems to a newly implemented Enterprise Resource Planning (“ERP”) system. The migration and implementation impacted operational processes, as well as certain accounti…

• Except with respect to the implementation of the ERP, there have been no changes in our internal control over financial reporting during the six-month period ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reportin…

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material informa…

• During the three-month period ended March 31, 2026, the Company migrated certain of our business applications and financial processing systems to a newly implemented Enterprise Resource Planning (ERP) system. The migration and implementation impacted operational processes, as well as certain account…

• Except with respect to the implementation of the ERP system, there have been no changes in our internal control over financial reporting during the three-month period ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financia…